These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3970857)

  • 1. Purification of antithrombin 'Vicenza': a molecule with normal heparin affinity and impaired reactivity to thrombin.
    Finazzi G; Tran TH; Barbui T; Duckert F
    Br J Haematol; 1985 Feb; 59(2):259-63. PubMed ID: 3970857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoelectrophoretic evidence of a thrombin-induced abnormality in a new variant of hereditary dysfunctional antithrombin III (AT III 'Vicenza').
    Barbui T; Finazzi G; Rodeghiero F; Dini E
    Br J Haematol; 1983 Aug; 54(4):561-5. PubMed ID: 6871107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal reactivity with thrombin of a new variant of dysfunctional antithrombin (AT 'Vicenza').
    Finazzi G; Barbui T; Tran TH; Duckert F
    Ric Clin Lab; 1984; 14(3):515-9. PubMed ID: 6522961
    [No Abstract]   [Full Text] [Related]  

  • 4. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombin III Northwick Park: demonstration of an inactive high MW complex with increased affinity for heparin.
    Lane DA; Flynn A; Ireland H; Erdjument H; Samson D; Howarth D; Thompson E
    Br J Haematol; 1987 Apr; 65(4):451-6. PubMed ID: 3580302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification and further characterization of antithrombin III Milano: lack of reactivity with thrombin.
    Wolf M; Boyer-Neumann C; Meyer D; Tripodi A; Mannucci PM; Larrieu MJ
    Thromb Haemost; 1987 Oct; 58(3):888-92. PubMed ID: 3433251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinction of two pathologic antithrombin III molecules: antithrombin III "Aalborg' and antithrombin III "Budapest'.
    Sørensen PJ; Sas G; Petó I; Blaskó G; Kremmer T; Samu A
    Thromb Res; 1982 May; 26(3):211-9. PubMed ID: 7112514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrate.
    Caso R; Lane DA; Thompson EA; Olds RJ; Thein SL; Panico M; Blench I; Morris HR; Freyssinet JM; Aiach M
    Br J Haematol; 1991 Jan; 77(1):87-92. PubMed ID: 1998601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").
    Sambrano JE; Jacobson LJ; Reeve EB; Manco-Johnson MJ; Hathaway WE
    J Clin Invest; 1986 Mar; 77(3):887-93. PubMed ID: 3512602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin.
    Ireland H; Lane DA; Thompson E; Walker ID; Blench I; Morris HR; Freyssinet JM; Grunebaum L; Olds R; Thein SL
    Br J Haematol; 1991 Sep; 79(1):70-4. PubMed ID: 1911389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the heterogeneity of antithrombin III concentrates.
    Barrowcliffe TW; Eggleton CA; Mahmoud M
    Br J Haematol; 1983 Sep; 55(1):37-46. PubMed ID: 6882687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombin III Glasgow: a variant with increased heparin affinity and reduced ability to inactivate thrombin, associated with familial thrombosis.
    Lane DA; Lowe GD; Flynn A; Thompson E; Ireland H; Erdjument H
    Br J Haematol; 1987 Aug; 66(4):523-7. PubMed ID: 3663509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification and properties of guinea pig antithrombin III.
    Heck L; Rosenberg R; Remold H
    Prep Biochem; 1979; 9(4):359-77. PubMed ID: 504072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and functional study of antithrombin III in newborn infants.
    McDonald MM; Hathaway WE; Reeve EB; Leonard BD
    Thromb Haemost; 1982 Feb; 47(1):56-8. PubMed ID: 7071806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the mechanism of the rate-enhancing effect of heparin on the thrombin-antithrombin III reaction.
    Holmer E; Söderström G; Andersson LO
    Eur J Biochem; 1979 Jan; 93(1):1-5. PubMed ID: 436823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A functional abnormal antithrombin III (AT III) deficiency: AT III Charleville.
    Aiach M; Nora M; Fiessinger JN; Roncato M; François D; Gelas MA
    Thromb Res; 1985 Sep; 39(5):559-70. PubMed ID: 4082101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S protein modulates the heparin-catalyzed inhibition of thrombin by antithrombin III. Evidence for a direct interaction of S protein with heparin.
    Preissner KT; Müller-Berghaus G
    Eur J Biochem; 1986 May; 156(3):645-50. PubMed ID: 3699029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A highly purified antithrombin III concentrate prepared from human plasma fraction IV-1 by affinity chromatography.
    Lebing WR; Hammond DJ; Wydick JE; Baumbach GA
    Vox Sang; 1994; 67(2):117-24. PubMed ID: 7801599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation, characterization and detection of a ternary complex between S protein, thrombin and antithrombin III in serum.
    Preissner KT; Zwicker L; Müller-Berghaus G
    Biochem J; 1987 Apr; 243(1):105-11. PubMed ID: 3606566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration.
    Collen D; Schetz J; de Cock F; Holmer E; Verstraete M
    Eur J Clin Invest; 1977 Feb; 7(1):27-35. PubMed ID: 65284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.